Turkish pharma major kicks off diabetes and hepatitis exports from Kazakhstan
Abdi İbrahim, a leading Turkish drugmaker, has commenced exports to Azerbaijan and Georgia from its Kazakhstan company, Abdi Ibrahim Global Pharm, which houses pharmaceutical production facilities.
Hepatitis and diabetes products from the largest and most modern pharmaceutical plant in Kazakhstan will be exported to both countries under the assurance of Abdi Ibrahim, the company stated.
Now in its 105th year of operation, Abdi Ibrahim has taken another firm step towards its 2020 targets through its Kazakhstan investment which marks the most significant component in its overseas investment portfolio. Abdi Ibrahim laid the foundations of the Kazakhstan facility in 2013. Soon after the launch of its operations, the production facility was awarded the GMP Certificate, which constitutes a reference document for best practices in manufacturing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze